news.cision.com

Metsä Group and Valmet are jointly developing a comprehensive operating model to ensure sustainability in technology and maintenance investments. The model will address various aspects of sustainability related to the environment, social responsibility and governance (ESG). It will be used to verify the sustainability of the process technology projects delivered by Valmet to Metsä Group and the related supply chains. Metsä Group and Valmet have set up a joint working group to develop and deploy the sustainability model. The goal is to adopt the model by 2027. “As part of its strategic

NIB’s third quarter results: Strong earnings and focus on green transition

During the first nine months of 2023, the Nordic Investment Bank (NIB) delivered net profits of EUR 195 million (EUR 84 million in the same period in 2022) and disbursed EUR 2,050 million (EUR 2,883 million).During the quarter, new loans were signed to finance marine decarbonisation and new renewable energy capacity and to strengthen the electricity distribution networks in the region, for example.NIB continued to prioritise high impact projects. During the first nine months of 2023, projects achieving a “good” or “excellent” mandate rating accounted for 99.8% of the total amount of

Valmet and Metsä Group to develop a joint sustainability model for industrial investment projects

Valmet Oyj’s press release on November 1, 2023 at 10:00 a.m. EETValmet and Metsä Group are jointly developing a comprehensive operating model to ensure sustainability in technology and maintenance investments. The model will address various aspects of sustainability related to the environment, social responsibility and governance (ESG). It will be used to verify the sustainability of the process technology projects delivered by Valmet to Metsä Group and the related supply chains. Valmet and Metsä Group have set up a joint working group to develop and deploy the sustainability model. The

Over one hundred theme cruises next year – special departures with both the latest trends and nostalgic vibes draw travellers

Wed, Nov 01, 2023 08:45 CET

For Finns, the destination or the travel programme is more and more often the reason they take a cruise. A record number of special cruises are being arranged next year – more than one hundred in all. The themes vary from champagne to stand-up comedy and from different musical genres to fashion. Today, there is an especially strong desire for relaxation and down-to-earth themes such as handicrafts and gardening.When tickets went on sale for the Kaija Koo special cruise on Viking Grace sailing next May, all 2,000 tickets sold out in two hours. Things are selling almost as quickly if

AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program

As previously announced, AegirBio AB, a leading innovator in saliva-based diagnostics solutions, has received a phase 1 award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for an accessibility project for multiplex testing.Today, AegirBio has received funds of $239,547. This award, totaling up to $1.2 million, enables AegirBio AB to commence work towards their continued pursuit of advancements in the field of at-home self-testing. "We are honored to have received the first installment of the RADx Tech award," said Marco Witteveen, CEO

Carbiotix reports promising results from CarbiAXOS metformin study

Wed, Nov 01, 2023 08:45 CET

Carbiotix (publ) ("Carbiotix" or the "Company") announces today promising preliminary results from the 4-month randomised controlled CarbiAXOS intervention study involving type-2 diabetes patients on metformin. The preliminary results reveal that 20% of patients in the intervention cohort responded positively to a prebiotic containing CarbiAXOS, experiencing an average improvement of 15% in HbA1c (blood glucose) levels and an upregulation of Short Chain Fatty Acid (SCFA) levels. These results are in line with our ambition, which was to replicate and substantiate the results from the 2018/2019

Observe Medical ASA: Proposed rights issue and notice of extraordinary general meeting in connection with the rights issue

Wed, Nov 01, 2023 08:41 CET

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Observe Medical ASA: Proposed rights issue and notice of extraordinary general meeting in connection with the rights issue

AegirBio focuses on RadX project, will not uphold CE-markings for the MagniaReader TDM tests

Wed, Nov 01, 2023 08:35 CET

AegirBio, a leading innovator in saliva-based diagnostics solutions, today announces that it will focus towards pioneering advancements in Therapeutic Drug Monitoring (TDM) through the development of a groundbreaking platform under the RadX initiative, coupled with a robust business development strategy.In line with this decision, AegirBio will continue to offer its current MagniaReader and the two TDM tests for the MagniaReader, albeit exclusively for research purposes and will thus not uphold the CE markings for the said PoC tests for infliximab (Remicade) and natalizumab (Tysabri). These

MTG increases ownership in PlaySimple to 100%

Modern Times Group MTG AB (publ) (“MTG”) today announced that it now owns 100% of its Indian casual gaming studios PlaySimple, in line with the timeline to full ownership announced at the time of the acquisition in 2021. At this stage MTG has not been able to transfer Class B shares (currently held by MTG as Class C shares ) to the founders of PlaySimple as per the original purchase agreement. MTG continues to strongly believe in the long-term benefits of having PlaySimple’s founders hold shares in the group, and intends to continue exploring options to achieve this.In order to explore

Invitation to presentation of BioArctic’s third quarter report for July - September 2023 on November 8 at 9.30 a.m. CET

Stockholm, Sweden, November 1, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)will publish the company’s third quarter report for July – September 2023 onWednesday, November 8, 2023, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on November 8, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present BioArctic and comment on the third quarter report for July – September 2023, followed by a Q&A-session. If you wish to participate via webcast, please use

The subscription price for the warrants of series TO3 in PEPTONIC medical AB has been determined to SEK 0.05 and the exercise period starts November 2, 2023

PEPTONIC medical AB ("Peptonic" or "the Company") completed a rights issue of units on Spotlight Stock Market in January 2023. Each warrant of series TO3 entitles to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO3 have been determined to 70 percent of the volume-weighted average price in the Company’s share on Spotlight Stock Market during the measurement period, which ran from and including October 18, 2023, up to and including October 31, 2023, however not higher than SEK 0.12 and not less than the quota value of the Company’s shares. During

YIT Corporation’s financial reporting and Annual General Meeting in 2024

YIT Corporation Stock Exchange Release 1 November 2023 at 09:30 a.m.YIT Corporation’s financial reporting and Annual General Meeting in 2024 YIT will publish the Financial Statements Bulletin for 2023 on Friday, 9 February 2024. Financial Statements 2023 will be published during week 8/2024 at the latest. In addition, YIT will publish two interim reports and a half-year report in 2024: · Interim Report for January-March on Tuesday, 30 April 2024 · Half-year Report for January-June on Friday, 26 July 2024 · Interim Report for January-September on Thursday, 31 October 2024

Metso's financial reporting and Annual General Meeting in 2024

Wed, Nov 01, 2023 08:28 CET

Metso Corporation’s stock exchange release on November 1, 2023, at 9:30 a.m. EETMetso Corporation will publish its financial reports in 2024 as follows: · Financial Statements Review for 2023 on February 16, 2024 · Annual Report for 2023 during the week of March 18, 2024 · Interim Report for January - March 2024 on April 25, 2024 · Half-Year Financial Report for January - June 2024 on July 24, 2024 · Interim Report for January – September 2024 on October 24, 2024 The Annual General Meeting is planned to be held on April 25, 2024. Metso’s Board of Directors will summon

Archer Limited: Invitation to Third Quarter 2023 Earnings Release Call

Hamilton, Bermuda (November 1[st], 2023) Archer Limited’s third quarter 2023 results are scheduled to be released on November 3[rd], 2023, before the start of trading on Oslo Stock Exchange. In connection with the earnings release, a presentation will be held at 09:00 am CET on November 3[rd], 2023. To follow the presentation, the following options are available: A. Webcast To register for the webcast please go to https://events.q4inc.com/attendee/991788945 B. Conference call To access the call, which is open to the public, please dial in at the participant telephone

BioStock: New CMO strengthens Lipum ahead of continued clinical development

Wed, Nov 01, 2023 08:23 CET

Lipum is in the final stages of the clinical phase I study with SOL-116. In parallel, the company is preparing for the next step, a phase II study in rheumatoid arthritis. To strengthen its team for this, the company has recently recruited Karin Franck-Larsson as CMO. BioStock had the opportunity to interview Karin about her background and her expectations for her new role.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/new-cmo-strengthens-lipum-ahead-of-continued-clinical-development/ This is a press release from BioStock - Connecting Innovation & Capital.

Photocure ASA: Invitation to presentation of third quarter 2023 financial results

Wed, Nov 01, 2023 08:21 CET

Oslo, Norway, 1 November 2023: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2023 financial results on Wednesday 8 November 2023 at 08:00 CET and will present a live webcast at 14:00 CET the same day.The quarterly report and presentation will be published at 08:00 CET and will be publicly available at www.photocure.com. The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45

AstraZeneca cell & gene therapy deal w/ Cellectis

01 November 2023 AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions Collaboration leverages the Cellectis gene editing technologies and manufacturing capabilities, to develop up to 10 novel cell and gene therapy candidate products AstraZeneca today announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Under

The exercise period for warrants TO5 in Dicot starts today

Press release: Uppsala, Sweden, November 1, 2023. Today, November 1, 2023, the exercise period for warrants of series TO5 in Dicot AB (publ), which were included in the unit issue in January 2023, begins. Subscription period lasts until November 15, 2023.Each warrant of series TO5 entitles the holder to subscribe to one new share during the period November 1-15, 2023, to the exercise price of SEK 0.086. If all warrants are exercised, Dicot will receive approximately SEK 19.4 million before issuing costs. The issue in January with its options TO4 in June and TO5 in November are all

Metso receives orders for three copper anode casting shops

Metso Corporation’s press release on November 1, 2023, at 09:00 a.m. EETMetso has received orders for three Outotec Anode Casting Shops from major copper producers in Japan and China. The total value of the orders is EUR 13 million. One of the orders has been booked in the Minerals segment’s 2023 fourth quarter orders received and two in the third quarter orders received. In each of the projects, Metso’s scope of delivery includes anode casting shops with engineering and state-of-the-art technology. “Today, most of the world’s copper anodes are produced with Metso’s proprietary anode

Camurus to present at Jefferies 2023 Healthcare Conference London

Lund, Sweden — 1 November 2023 — Camurus (Nasdaq Stockholm; CAMX), a commercial-stage pharmaceutical company developing innovative medications for severe and chronic diseases, today announced that Fredrik Tiberg, President and Chief Executive Officer, will participate in a fireside chat about the company’s business progress and R&D pipeline developments at Jefferies 2023 Healthcare Conference in London on 15 November at 8:30-8:55 am local time (GMT). A live webcast of the presentation can be accessed via: https://wsw.com/webcast/jeff287/camx.st/2248776 For more informationFredrik

Betolar accelerates the commercialisation of its mining solutions